Chapter III: Management of cardiovascular risk factors and medical therapy

European Journal of Vascular and Endovascular Surgery

Volumn 42, Issue SUPPL. 2, 2011, Pages

  Diehm, N ^a   Schmidli, J ^a   Setacci, C ^b   Ricco, J B ^c   De Donato, G ^d   Becker, F ^e   Robert Ebadi, H ^e   Cao, P ^f   Eckstein, H H ^g   De Rango, P ^h   Teraa, M ^a,d   Moll, F L ^d   Dick, F ^a   Davies, A H ⁱ   Lepantalo M ^j,k   Apelqvist, J ^l,m  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF SIENA   (Italy)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY OF PERUGIA   (Italy)

ⁱ CHARING CROSS HOSPITAL   (United Kingdom)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k UNIVERSITY OF HELSINKI   (Finland)

^l LUND UNIVERSITY HOSPITAL   (Sweden)

^m LUND UNIVERSITY   (Sweden)

more..

Author keywords

Conservative treatment; Medication; Risk factor modification

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; METOPROLOL; METOPROLOL SUCCINATE; PLACEBO; PROSTAGLANDIN E1; PROSTANOID; TICLOPIDINE;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; DIET; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HEALTH ECONOMICS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LEG REVASCULARIZATION; LIMB ISCHEMIA; LOW DRUG DOSE; NEUTROPENIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REHABILITATION MEDICINE; RENAL ARTERY DISEASE; RISK FACTOR; SMOKING CESSATION; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; WALKING;

ADRENERGIC BETA-ANTAGONISTS; ARTERIAL OCCLUSIVE DISEASES; CRITICAL ILLNESS; DIABETES MELLITUS; DIABETIC FOOT; DIET; EXERCISE THERAPY; GENE THERAPY; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; ISCHEMIA; LOWER EXTREMITY; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDINS; RISK ASSESSMENT; RISK FACTORS; SMOKING CESSATION; STEM CELL TRANSPLANTATION; VASCULAR SURGICAL PROCEDURES;

EID: 83455203485     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/S1078-5884(11)60011-7     Document Type: Article

References (79)

1. AT Hirsch, D Treat-Jacobson, HA Lando, DK Hatsukami The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease Vasc Med 2 3 1997 243 251 (Pubitemid 27468159)
2. L Norgren, WR Hiatt, JA Dormandy, MR Nehler, KA Harris, FG Fowkes et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) Eur J Vasc Endovasc Surg 33 Suppl 1 2007 S1 75
3. EM Willigendael, JA Teijink, ML Bartelink, RJ Peters, HR Buller, MH Prins Smoking and the patency of lower extremity bypass grafts: a meta-analysis J Vasc Surg 42 1 2005 67 74 (Pubitemid 40966078)
4. LF Stead, R Perera, C Bullen, D Mant, T Lancaster Nicotine replacement therapy for smoking cessation Cochrane Database Syst Rev 1 2008 CD000146
5. S Tonstad, C Farsang, G Klaene, K Lewis, A Manolis, AP Perruchoud et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study Eur Heart J 24 10 2003 946 955 (Pubitemid 36559988)
6. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2:CD006103.
7. JF Etter Short-term change in self-reported COPD symptoms after smoking cessation in an internet sample Eur Respir J 35 6 2010 1249 1255
8. A Roux, P Motreff, J Perriot, B Pereira, JR Lusson, C Duale et al. Early improvement in peripheral vascular tone following smoking cessation using nicotine replacement therapy: aortic wave reflection analysis Cardiology 117 1 2010 37 43
9. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
10. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 9326 2002 7 22
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 8934 1994 1383 1389
12. MS Conte, DF Bandyk, AW Clowes, GL Moneta, H Namini, L Seely Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial J Vasc Surg 42 3 2005 456 464 discussion 464-55 (Pubitemid 41323832)
13. PP Aung, HG Maxwell, RG Jepson, JF Price, GC Leng Lipid-lowering for peripheral arterial disease of the lower limb Cochrane Database Syst Rev 4 2007 CD000123.
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 25 2002 3143 3421
15. B Sadowitz, KG Maier, V Gahtan Basic science review: Statin therapy - Part I: The pleiotropic effects of statins in cardiovascular disease Vasc Endovascular Surg 44 4 2010 241 251
16. SM Grundy, JI Cleeman, CN Merz, HB Brewer Jr, LT Clark, DB Hunninghake et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Arterioscler Thromb Vasc Biol 24 8 2004 e149 e161
17. G De Backer, E Ambrosioni, K Borch-Johnsen, C Brotons, R Cifkova, J Dallongeville et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) Atherosclerosis 173 2 2004 381 391
18. S Chaturvedi The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): is it really practical? Natl Med J India 17 2004 (4):227
19. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 21 6 2003 1011 1053
20. S Yusuf, P Sleight, J Pogue, J Bosch, R Davies, G Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 3 2000 145 153
21. U Thadani, TL Whitsett Beta-adrenergic blockers and intermittent claudication. Time for reappraisal Arch Intern Med 151 9 1991 1705 1707
22. SC Paravastu, DA Mendonca, A da Silva Beta blockers for peripheral arterial disease Eur J Vasc Endovasc Surg 38 1 2009 66 70
23. K Radack, C Deck Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials Arch Intern Med 151 9 1991 1769 1776
24. D Poldermans, JJ Bax, E Boersma, S De Hert, E Eeckhout, G Fowkes et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery Eur Heart J 30 22 2009 2769 2812
25. PJ Devereaux, H Yang, S Yusuf, G Guyatt, K Leslie, JC Villar et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial Lancet 371 9627 2008 1839 1847
26. D Poldermans, JJ Bax, E Boersma, S De Hert, E Eeckhout, G Fowkes et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA) Eur J Anaesthesiol 27 2 2010 92 137
27. P Gaede, H Lund-Andersen, HH Parving, O Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 6 2008 580 591 (Pubitemid 351214285)
28. RR Holman, SK Paul, MA Bethel, DR Matthews, HA Neil 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 15 2008 1577 1589
29. A Patel, S MacMahon, J Chalmers, B Neal, L Billot, M Woodward et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 24 2008 2560 2572 (Pubitemid 351831357)
30. HC Gerstein, ME Miller, S Genuth, F Ismail-Beigi, JB Buse, DC Goff Jr ACCORD Study Group Long-term effects of intensive glucose lowering on cardiovascular outcomes N Engl J Med 364 9 2011 818 828
31. WH Geerts, D Bergqvist, GF Pineo, JA Heit, CM Samama, MR Lassen et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 Suppl 2008 381S 453S (Pubitemid 351894916)
32. CAPRIE Steering Committee A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
33. Antithrombotic Trialists' Collaboration Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
34. GP Clagett, M Sobel, MR Jackson, GYH Lip, M Tangelder, RH Verhaeghe Antithrombotic Therapy in Peripheral Arterial Occlusive Disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 3 2004 609S 626S (Pubitemid 39297965)
35. C Diehm, A Schuster, JR Allenberg, H Darius, R Haberl, S Lange et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study Atherosclerosis 172 1 2004 95 105 (Pubitemid 38058606)
36. P Poredos, MK Jezovnik Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease Int Angiol 29 1 2010 20 26
37. VL Serebruany, SR Steinhubl, PB Berger, AI Malinin, JS Baggish, DL Bhatt et al. Analysis of risk of bleeding complications after different doses of aspirin in 192, 036 patients enrolled in 31 randomized controlled trials Am J Cardiol 95 10 2005 1218 1222 (Pubitemid 40616424)
38. L Janzon, D Bergqvist, J Boberg, M Boberg, I Eriksson, F Lindgarde et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study J Intern Med 227 5 1990 301 308 (Pubitemid 20137140)
39. S Anand, S Yusuf, C Xie, J Pogue, J Eikelboom, A Budaj et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease N Engl J Med 357 3 2007 217 227 (Pubitemid 47080386)
40. HW Heiss, H Just, D Middleton, G Deichsel Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA Angiology 41 4 1990 263 269 (Pubitemid 20164472)
41. Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial. Study group on pharmacological treatment after PTA Eur J Vasc Surg 8 1 1994 83 88
42. JJ Belch, J Dormandy, GM Biasi, M Cairols, C Diehm, B Eikelboom et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial J Vasc Surg 52 4 2010 825 833 833.e1-2
43. W Weichert, H Meents, K Abt, H Lieb, W Hach, HJ Krzywanek et al. Acetylsalicylic acid-reocclusion-prophylaxis after angioplasty (ARPA-study). A randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease Vasa 23 1 1994 57 65 (Pubitemid 24077817)
44. J Dorffler-Melly, MM Koopman, MH Prins, HR Buller Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment Cochrane Database Syst Rev 1 2005 CD002071.
45. C Ranke, A Creutzig, G Luska, HH Wagner, M Galanski, S Bode-Boger et al. Controlled trial of high-versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease Clin Invest 72 9 1994 673 680 (Pubitemid 24304084)
46. SR Mehta, S Yusuf, RJ Peters, ME Bertrand, BS Lewis, MK Natarajan et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 9281 2001 527 533 (Pubitemid 32772726)
47. Menzoian J. Major leg amputations in patients with severe peripheral arterial occlusive disease (PAD) not amenable to revascularization procedures: results of a randomized, placebo-controlled multicenter study with alprostadil. Paper presented at 17th World Congress of the International Union of Angiology (IUA). Abstract Book; 1995.
48. H Stiegler, C Diehm, E Grom, M Martin, H Morl, G Rudofsky et al. [Placebo controlled, double-blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease] Vasa Suppl 35 1992 164 166 (Pubitemid 23004241)
49. HO Altstaedt, B Berzewski, HK Breddin, W Brockhaus, HD Bruhn, M Cachovan et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study Prostaglandins Leukot Essent Fatty Acids 49 2 1993 573 578 (Pubitemid 23236517)
50. A Creutzig, W Lehmacher, M Elze Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV Vasa 33 3 2004 137 144 (Pubitemid 39141713)
51. TM Loosemore, TC Chalmers, JA Dormandy A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease Int Angiol 13 2 1994 133 142 (Pubitemid 24248101)
52. FB Smith, AW Bradbury, FG Fowkes Intravenous naftidrofuryl for critical limb ischaemia Cochrane Database Syst Rev 2 2000 CD002070
53. RJ Powell, P Goodney, FO Mendelsohn, EK Moen, BH Annex Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial J Vasc Surg 52 6 2010 1525 1530
54. S Nikol, I Baumgartner, E Van Belle, C Diehm, A Visona, MC Capogrossi et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia Mol Ther 16 5 2008 972 978 (Pubitemid 351587109)
55. K Makinen, H Manninen, M Hedman, P Matsi, H Mussalo, E Alhava et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study Mol Ther 6 1 2002 127 133 (Pubitemid 36124280)
56. YH Kusumanto, V van Weel, NH Mulder, AJ Smit, JJ van den Dungen, JM Hooymans et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial Hum Gene Ther 17 6 2006 683 691 (Pubitemid 43970708)
57. WR Hiatt, I Baumgartner, S Nikol, E Van Belle, E Driver, L Norgren et al. http://www.slideshare.net/alizotte/aha-tamaris
58. E Tateishi-Yuyama, H Matsubara, T Murohara, U Ikeda, S Shintani, H Masaki for the Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlled trial Lancet 360 2002 427 435
59. H Lawall, P Bramlage, B Amann Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal Thromb Haemost 103 4 2010 696 709
60. RW Sprengers, FL Moll, MC Verhaar Stem cell therapy in PAD Eur J Vasc Endovasc Surg 39 Suppl 1 2010 S38 S43
61. DL Bhatt, PG Steg, EM Ohman, AT Hirsch, Y Ikeda, JL Mas et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis JAMA 295 2 2006 180 189 (Pubitemid 43076437)
62. DL Clement, H Boccalon, J Dormandy, I Durand-Zaleski, G Fowkes, T Brown A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis) Int Angiol 19 2 2000 97 125 (Pubitemid 30406580)
63. JL Anderson, CD Adams, EM Antman, CR Bridges, RM Califf, DE Casey Jr et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 123 18 2011 e426 e579
64. TD Fraker Jr, SD Fihn, RJ Gibbons, J Abrams, K Chatterjee, J Daley et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina J Am Coll Cardiol 50 23 2007 2264 2274 (Pubitemid 350166813)
65. LA Fleisher, JA Beckman, KA Brown, H Calkins, EL Chaikof, KE Fleischmann et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery J Am Coll Cardiol 50 17 2007 1707 1732
66. EO McFalls, HB Ward, TE Moritz, S Goldman, WC Krupski, F Littooy et al. Coronary-artery revascularization before elective major vascular surgery N Engl J Med 351 27 2004 2795 2804 (Pubitemid 40051903)
67. D Poldermans, E Boersma, JJ Bax, IR Thomson, LL van de Ven, JD Blankensteijn et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group N Engl J Med 341 24 1999 1789 1794
68. D Poldermans, E Boersma, JJ Bax, IR Thomson, B Paelinck, LL van de Ven et al. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery Eur Heart J 22 15 2001 1353 1358 (Pubitemid 32737628)
69. MD Kertai, E Boersma, JJ Bax, IR Thomson, MJ Cramer, LL van de Ven et al. Optimizing long-term cardiac management after major vascular surgery: Role of beta-blocker therapy, clinical characteristics, and dobutamine stress echocardiography to optimize long-term cardiac management after major vascular surgery Arch Intern Med 163 18 2003 2230 2235 (Pubitemid 37248788)
70. TG Brott, JL Halperin, S Abbara, JM Bacharach, JD Barr, RL Bush et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery J Neurointerv Surg 3 2 2011 100 130
71. AT Hirsch, ZJ Haskal, NR Hertzer, CW Bakal, MA Creager, JL Halperin et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation J Am Coll Cardiol 47 6 2006 1239 1312
72. PF Plouin, DL Clement, H Boccalon, J Dormandy, I Durand-Zaleski, G Fowkes et al. A clinical approach to the management of a patient with suspected renovascular disease who presents with leg ischemia Int Angiol 22 4 2003 333 339 (Pubitemid 38331906)
73. JH Rundback, D Sacks, KC Kent, C Cooper, D Jones, T Murphy et al. Guidelines for the reporting of renal artery revascularization in clinical trials J Vasc Interv Radiol 14 9 Pt 2 2003 S477 S492
74. S Mistry, N Ives, J Harding, K Fitzpatrick-Ellis, G Lipkin, PA Kalra et al. Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far J Hum Hypertens 21 7 2007 511 515 (Pubitemid 47018623)
75. JM Gaspoz, PG Coxson, PA Goldman, LW Williams, KM Kuntz, MG Hunink et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease N Engl J Med 346 2002 1800 1806 (Pubitemid 34586917)
76. MA Fischer, J Avorn Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA 291 15 2004 1850 1856 (Pubitemid 38509497)
77. MK Ito, D Nanchen, N Rodondi, F Paccaud, G Waeber, P Vollenweider et al. Statins for cardiovascular prevention according to different strategies: a cost analysis Am J Cardiovasc Drugs 11 1 2011 33 44
78. DL Bhatt, KA Fox, W Hacke, PB Berger, HR Black, WE Boden et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 16 2006 1706 1717
79. B Mihaylova, A Briggs, J Armitage, S Parish, A Gray, R Collins Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20, 536 individuals Lancet 365 9473 2005 1779 1785